Abstract:Tuberculosis is reported to be associated with the severity and mortality amongst patients with coronavirus disease 2019 (COVID-19).1 However, the reported prevalence of comorbid tuberculosis amongst COVID-19 patients varied greatly across the published studies. For example, the low prevalence of comorbid tuberculosis amongst COVID-19 patients was reported in Tian et al's study (0.4%)2 and Yan et al's study (0.2%)3 and the relatively high prevalence of comorbid tuberculosis amongst COVID-19 patients was reported in Hu et al's study (4.5%)4 and Zhang et al's study (9.0%).5 Therefore, it is needed to quantitatively estimate the pooled prevalence of comorbid tuberculosis amongst COVID-19 patients using a meta-analysis. A systematic literature search was conducted independently by two investigators in PubMed, Web of Science, EMBASE, Springer, Elsevier-ScienceDirect, Wiley Online Library, Scopus and Cochrane Library databases to select all eligible studies which were published from 1 January 2020 to 31 August 2021. The following keywords were used: "prevalence" or "incidence" or "rate" or "characteristics" and "tuberculosis" and "COVID-19" or "SARS-CoV-2" or "2019-nCoV" or "severe acute respiratory syndrome coronavirus 2" or "coronavirus disease 2019" or "2019 novel coronavirus". All peer-reviewed papers which were published in the English language were eligibly included if they provided the incidence rate of comorbid tuberculosis amongst COVID-19 patients. Accordingly, we excluded case reports, review articles, duplicate publications, errata, comments and preprints. Reference lists of the retrieved articles were also screened to identify additional studies. This rapid systematic review and meta-analysis was performed following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).6 The pooled prevalence of comorbid tuberculosis amongst COVID-19 patients was estimated using a random effects meta-analysis model.7, 8 The statistical heterogeneity across studies was assessed by I2 statistic and Cochrane Q test.9, 10 The risk of publication bias was evaluated by Begg's rank correlation test.11, 12 All statistical analyses were carried out using the package "meta" on R version 3.6.3 (R Foundation for Statistical Computing). A two-tailed P value <.05 was regarded statistically significant. A total of 114 eligible studies2-5, 13-122 with 405 596 COVID-19 patients were included in this meta-analysis. Amongst the included studies, 77 studies2-5, 13-85 were reported in Asia, 15 studies90-100 were conducted in Africa, nine studies101-109 were conducted in South America, five studies110-114 were performed in North America, seven studies115-121 were conducted in Europe and one study122 was from multicountries. The baseline characteristics of the included studies are summarised in Table 1. Overall, our findings demonstrated that the prevalence of comorbid tuberculosis amongst COVID-19 patients in this pooled meta-analysis was 1.6% with 95% confidence interval (CI): 1.3%–1.9% (Figure 1). The regional tuberculosis prevalence in COVID-19 patients was estimated as follows: Africa (4.1%, 95% CI: 0.0%–5.8%), Asia (1.1%, 95% CI: 0.9%–1.3%), South America (0.5%, 95% CI: 0.0%–1.0%), Europe (0.4%, 95% CI: 0.0%–0.6%) and North America (0.2%, 95% CI: 0.0%–0.4%), which revealed great variability in the prevalence of comorbid tuberculosis amongst COVID-19 patients in different regions. Begg's test revealed that there was potential publication bias (P = .0017). In conclusion, our findings demonstrated that the prevalence of comorbid tuberculosis amongst COVID-19 patients was 1.6%, which varied greatly in different regions. We would like to thank Wenwei Xiao, Xuan Liang, Peihua Zhang, Yang Li and Jian Wu (All are from Department of Epidemiology, School of Public Health, Zhengzhou University) for their kind help in searching articles and collecting data. The authors declare that they have no any potential conflict of interest regarding this submitted manuscript. Yadong Wang and Haiyan Yang designed the study. Jie Xu, Ying Wang, Hongjie Hou and Li Shi performed literature search and data extraction. Jie Xu and Yadong Wang performed data analysis. Yadong Wang and Haiyan Yang wrote and reviewed the manuscript. All the authors approved the final manuscript. The data that support the findings of this study are included in this article and available from the corresponding author upon reasonable request.

Comorbidity and Its Impact on 1,590 Patients with COVID-19 in China: A Nationwide Analysis

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China

The Clinical Characteristics and Prognosis of COVID-19 Patients with Comorbidities: a Retrospective Analysis of the Infection Peak in Wuhan.

Impact of Chronic Comorbidities on Progression and Prognosis in Patients with COVID-19: A Retrospective Cohort Study in 1031 Hospitalized Cases in Wuhan, China

Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis

Prevalence of Comorbid Tuberculosis Amongst COVID‐19 Patients: A Rapid Review and Meta‐analysis

Prevalence of Comorbidities and Its Effects in Patients Infected with SARS-CoV-2: a Systematic Review and Meta-Analysis

Comorbidity and its Impact on Patients with COVID-19

Number of Pre-Existing Comorbidities and Prognosis of COVID-19: A Retrospective Cohort Study

Risk Factors for Adverse Clinical Outcomes with COVID-19 in China: a Multicenter, Retrospective, Observational Study

Not Only High Number and Specific Comorbidities but Also Age Are Closely Related to Progression and Poor Prognosis in Patients with COVID-19

Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study

Patient Predisposition at Hospital Admission Indirectly Dictates Disease Severity, Clinical Course and Outcomes of COVID-19 Pneumonia Patients in Wuhan, China

Epidemiological and Clinical Characteristics of 1663 Hospitalized Patients Infected with COVID-19 in Wuhan, China: a Single-Center Experience

Clinical Characteristics and Prognosis of 218 Patients With COVID-19: A Retrospective Study Based on Clinical Classification

Association of Clinical and Immunological Characteristics With Disease Severity and Outcomes in 211 Patients With COVID-19 in Wuhan, China

Old Age, Number and Specific Comorbidities are Closely Related to Progression and Poor Prognosis in Patients with COVID-19

Comorbidities and the Risk of Severe or Fatal Outcomes Associated with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis

Clinical Features and Short-Term Outcomes of 221 Patients with COVID-19 in Wuhan, China.

Impact of Comorbidity on the Duration from Symptom Onset to Death in Patients with Coronavirus Disease 2019: A Retrospective Study of 104,753 Cases in Pakistan.